Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
CIAN HEALTHCARE ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIAN HEALTHCARE Mar-23 |
ADCOCK INGRAM Jun-14 |
CIAN HEALTHCARE/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 32 | 327 | - | |
Low | Rs | 12 | 236 | - | |
Sales per share (Unadj.) | Rs | 27.4 | 97.3 | - | |
Earnings per share (Unadj.) | Rs | 0.8 | -24.5 | - | |
Cash flow per share (Unadj.) | Rs | 3.0 | -20.3 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 23.0 | 76.3 | - | |
Shares outstanding (eoy) | m | 25.00 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.8 | 2.9 | 27.6% | |
Avg P/E ratio | x | 27.0 | -11.5 | -235.4% | |
P/CF ratio (eoy) | x | 7.4 | -13.9 | -53.1% | |
Price / Book Value ratio | x | 1.0 | 3.7 | 25.9% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 549 | 47,499 | 1.2% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 89 | 2,981 | 3.0% | |
Avg. sales/employee | Rs Th | 0 | 3,824.0 | - | |
Avg. wages/employee | Rs Th | 0 | 694.4 | - | |
Avg. net profit/employee | Rs Th | 0 | -963.6 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 686 | 16,416 | 4.2% | |
Other income | Rs m | 6 | 115 | 5.4% | |
Total revenues | Rs m | 692 | 16,531 | 4.2% | |
Gross profit | Rs m | 131 | -2,845 | -4.6% | |
Depreciation | Rs m | 54 | 709 | 7.7% | |
Interest | Rs m | 63 | 445 | 14.2% | |
Profit before tax | Rs m | 20 | -3,883 | -0.5% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 243 | -0.2% | |
Profit after tax | Rs m | 20 | -4,137 | -0.5% | |
Gross profit margin | % | 19.1 | -17.3 | -110.2% | |
Effective tax rate | % | -1.9 | -6.2 | 31.1% | |
Net profit margin | % | 3.0 | -25.2 | -11.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 742 | 12,024 | 6.2% | |
Current liabilities | Rs m | 653 | 6,765 | 9.6% | |
Net working cap to sales | % | 13.1 | 32.0 | 40.9% | |
Current ratio | x | 1.1 | 1.8 | 64.0% | |
Inventory Days | Days | 94 | 111 | 85.0% | |
Debtors Days | Days | 1,396 | 124 | 1,126.2% | |
Net fixed assets | Rs m | 762 | 7,009 | 10.9% | |
Share capital | Rs m | 250 | 76 | 327.9% | |
Net worth | Rs m | 575 | 12,885 | 4.5% | |
Long term debt | Rs m | 294 | 4,528 | 6.5% | |
Total assets | Rs m | 1,605 | 24,341 | 6.6% | |
Interest coverage | x | 1.3 | -7.7 | -17.0% | |
Debt to equity ratio | x | 0.5 | 0.4 | 145.5% | |
Sales to assets ratio | x | 0.4 | 0.7 | 63.4% | |
Return on assets | % | 5.2 | -15.2 | -34.2% | |
Return on equity | % | 3.5 | -32.1 | -11.0% | |
Return on capital | % | 9.5 | -19.8 | -48.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 48 | 1,401 | 3.5% | |
From Investments | Rs m | 26 | -430 | -5.9% | |
From Financial Activity | Rs m | -74 | 4,110 | -1.8% | |
Net Cashflow | Rs m | 0 | 5,081 | -0.0% |
Compare CIAN HEALTHCARE With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare CIAN HEALTHCARE With: MANGALAM DRUGS GUJ.THEMIS. BLISS GVS PHARMA JAGSON PHAR PARABOLIC DRUGS
Indian share markets Slipped further as the session progressed and ended the day weak.